Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature
- 1 November 2007
- journal article
- case report
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 12 (11) , 1332-1335
Abstract
Learning Objectives: After completing this course, the reader will be able to: Describe the clinical and radiologic manifestations of RPLS.Define agents or inciting risk factors that have been implicated in the development of RPLS.Describe the treatment and outcome of RPLS, emphasizing supportive care and urgent discontinuation of the offending agent. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.comKeywords
This publication has 21 references indexed in Scilit:
- Dexamethasone-Induced Posterior Reversible Encephalopathy SyndromeJournal of Clinical Oncology, 2007
- Reversible posterior leukoencephalopathy syndrome after repeat intermediate‐dose cytarabine chemotherapy in a patient with acute myeloid leukemiaAmerican Journal of Hematology, 2007
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJournal of Clinical Oncology, 2006
- Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006Journal of Clinical Oncology, 2006
- Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trialLung Cancer, 2006
- Reversible Posterior Leukoencephalopathy Syndrome and BevacizumabNew England Journal of Medicine, 2006
- A case of reversible posterior leucoencephalopathy syndrome after rituximab infusionRheumatology, 2004
- Severe neurotoxicity caused by gemcitabine treatmentActa Oncologica, 2004
- Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignanciesAmerican Journal of Hematology, 2004
- Gemcitabine plus Paclitaxel as First-Line Chemotherapy for Patients with Advanced Breast CancerOncology, 2004